Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as lintuzumab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. Giving chemotherapy together with monoclonal
antibodies may be a better way to block cancer growth.
PURPOSE: This phase II trial is studying the side effects and how well giving azacitidine
together with lintuzumab works in treating patients with previously untreated myelodysplastic
syndromes.